Ralliant (NYSE:RAL) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

A number of other brokerages have also issued reports on RAL. Oppenheimer boosted their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Morgan Stanley raised their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. TD Cowen upped their target price on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 20th. Finally, Truist Financial reiterated a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ralliant presently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Trading Down 2.3%

Shares of NYSE RAL opened at $71.93 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $8.05 billion and a PE ratio of -6.57. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41. The stock has a fifty day simple moving average of $59.71 and a 200-day simple moving average of $51.69.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. Ralliant’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Hedge Funds Weigh In On Ralliant

Several hedge funds and other institutional investors have recently made changes to their positions in RAL. Pacer Advisors Inc. acquired a new position in shares of Ralliant during the first quarter worth about $201,000. Empowered Funds LLC raised its holdings in Ralliant by 36.3% in the first quarter. Empowered Funds LLC now owns 5,478 shares of the company’s stock valued at $228,000 after acquiring an additional 1,459 shares in the last quarter. First Nebraska Trust Co purchased a new position in Ralliant in the first quarter worth approximately $435,000. Irenic Capital Management LP lifted its stake in Ralliant by 424.1% in the first quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock worth $72,376,000 after acquiring an additional 1,408,176 shares during the last quarter. Finally, Amundi grew its holdings in Ralliant by 6.2% during the 1st quarter. Amundi now owns 148,614 shares of the company’s stock worth $6,181,000 after acquiring an additional 8,649 shares in the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.